Literature DB >> 18990082

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.

Seetal Dodd1, Olivia Dean, David L Copolov, Gin S Malhi, Michael Berk.   

Abstract

BACKGROUND: Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body's defences. Treatment with N-acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses.
OBJECTIVES: The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication.
METHODS: A literature search was conducted using PubMed. Information was also collected from other online sources including the websites of the Therapeutic Goods Administration of Australia and the FDA.
RESULTS: Reports ranged from case studies to clinical trials. There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder. NAC is safe and well tolerated when administered orally but has documented risks with intravenous administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990082     DOI: 10.1517/14728220802517901

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  109 in total

1.  Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

Authors:  Thomas D Nolin; Rosemary Ouseph; Jonathan Himmelfarb; M Elizabeth McMenamin; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism.

Authors:  Stepan Melnyk; George J Fuchs; Eldon Schulz; Maya Lopez; Stephen G Kahler; Jill J Fussell; Jayne Bellando; Oleksandra Pavliv; Shannon Rose; Lisa Seidel; David W Gaylor; S Jill James
Journal:  J Autism Dev Disord       Date:  2012-03

Review 3.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study.

Authors:  Eduardo Prado; Michael Maes; Luiz Gustavo Piccoli; Marcela Baracat; Décio Sabattini Barbosa; Olavo Franco; Seetal Dodd; Michael Berk; Sandra Odebrecht Vargas Nunes
Journal:  Redox Rep       Date:  2015-03-02       Impact factor: 4.412

Review 5.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

6.  N-acetylcysteine protects pancreatic islet against glucocorticoid toxicity.

Authors:  Letícia P Roma; Camila A M Oliveira; Everardo M Carneiro; Gabriela G Albuquerque; Antonio C Boschero; Kleber L A Souza
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 7.  Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.

Authors:  Xingguo Zhu; Aluya R Oseghale; Lopez H Nicole; Biaoru Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-23

8.  Studies of the metabotropic glutamate receptor 5 radioligand [¹¹C]ABP688 with N-acetylcysteine challenge in rhesus monkeys.

Authors:  Christine M Sandiego; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Soheila Najafzadeh; Yiyun Huang; Kelly Cosgrove; Richard E Carson
Journal:  Synapse       Date:  2013-03-27       Impact factor: 2.562

9.  Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats.

Authors:  Samah G Abdel Baki; Ben Schwab; Margalit Haber; André A Fenton; Peter J Bergold
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

10.  Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy.

Authors: 
Journal:  Trials       Date:  2009-06-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.